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Re-epithelialization is a crucial step towards wound healing. The traditional Chinese medicine, Astragalus membranaceus (Fisch)
Bge, has been used for hundreds of years for many kinds of ulcerated wounds. Recent research has identiﬁed the active compound
in this drug as astragaloside IV (AS-IV), but the underlying molecular mechanisms of its therapeutic action on keratinocytes
remain poorly understood. In this study, we used an in vitro model of ulcer-like wound processes, lithium chloride (LiCl)-induced
cultured mouse keratinocytes, to investigate the eﬀects of AS-IV treatment. The eﬀects on cell proliferation were evaluated by the
MTS/PMS colorimetric assay, eﬀects on cell migration were determined by a wound-healing scratch experiment, eﬀects on the
cell cycle were analyzed by ﬂow cytometry, and eﬀects on protein expression were analyzed by immunoblotting and immuno-
ﬂuorescence. LiCl strongly inhibited cell proliferation and migration, up-regulated β-catenin expression, and down-regulated
proliferating cell nuclear antigen (PCNA) expression. AS-IV treatment attenuat the inhibition of proliferation and migration,
signiﬁcantly reducing the enhanced β-catenin expression, and recovering PCNA and β-tubulin expression. Thus, AS-IV mediates
mouse keratinocyte proliferation and migration via regulation of the Wnt signaling pathway. Down-regulating β-catenin to
increase keratinocyte migration and proliferation is one mechanism by which AS-IV can promote ulcerated wound healing.
1.Introduction
The skin of all animals provides a protective barrier against
entry by pathogens and environmental toxins. Skin cells
also encompass a rich molecular infrastructure that involves
immune system processes, which further defend against
disease or injury to the underlying organs. Thus, cutaneous
wounds not only aﬀect skin homeostasis, but also represent a
systemic threat; thus, the wound healing process is critical
for general health and well-being [1]. The wound healing
process is intricate and not yet fully understood; however, it
is known that many underlying conditions, such as diabetes,
cancer, and vascular disease, can prolong or block the
process. In those cases, normal trauma caused by a simple
accident or fall can become an ulcerated chronic wound,
signiﬁcantlyimpactingone’squalityoflifeandincreasingthe
risk of death.
For many centuries, the world’s physicians have sought
out methods and therapeutic agents that will promote and
accelerate wound healing [2]. Generally, the cutaneous
woundhealingprocesscanbedividedintothreeoverlapping,
but distinct, phases: the inﬂammatory phase, the prolifera-
tive phase (neoangiogenesis, tissue formation, reepithelial-
ization) and the tissue remodeling phase [3–5]. Reepithelial-
ization is considered a crucial step towards wound healing,
and impairment of this process has been demonstrated to
result in the development of chronic wounds [6].
The traditional Chinese medicine, Astragalus mem-
branaceus ( F i s c h )B g e ,h a sl o n gb e e nu s e dt ot r e a tu l c e r a t e d
wounds.Recently,themainactivecompoundfromthisdrug,2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Chemical structure of astragaloside IV.
astragaloside IV (AS-IV), a 3-O-β-D-xylopyranosyl-6-O-β-
D-glucopyranosylcycloastragenol (chemical structureshown
inFigure 1),waspuriﬁed.Researchstudiesintothebiological
properties of AS-IV have revealed strong anti-inﬂammatory
activity, which involves inhibition of NF-κBa c t i v a t i o n
and downregulation of adhesion molecule expression [7].
In addition, many other pharmacological activities have
been demonstrated, including antidiabetic and antioxidative
activities [8]. However, the precise mechanisms by which
AS-IV promotes wound healing remain to be elucidated. In
order to develop this Chinese herb as a bona ﬁde therapeutic
agent to treat aberrant wound healing, it is necessary to
gain a detailed understanding of the involved cellular and
molecular mechanisms.
It is known that activation of β-catenin/c-myc pathways
can inhibit keratinocyte migration and diﬀerentiation,
thereby impairing wound healing [9]. Prior studies using
embryological models indicated that administration of
lithium chloride (LiCl) can induce signaling pathways that
mimic Wnt/β-catenin activation. Speciﬁcally, LiCl treatment
inhibits GSK-3β activity by inducing phosphorylation at
Ser-9 [10], which in turn, stabilizes free cytosolic β-catenin.
Thus, in vitro treatment of cultured keratinocytes with LiCl
allows for the controlled experimental analysis of the molec-
ular processes underlying impeded wound healing.
Activated β-catenin and c-myc have been clinically
detected in the epidermis of chronic wounds. As such, it has
been proposed that these molecules may serve as markers
of impaired healing and may represent useful targets of
therapeutic intervention [9]. In a previous study, we demon-
strated that diabetic skin ulcers can be eﬃciently managed
by treatment with a Chinese medicine cocktail that includes
Astragalus membranaceus (Fisch) Bge. We hypothesized that
the mechanism of action might involve inhibition of the
Wnt signaling pathway [11]. The study presented herein
was designed to investigate the potential eﬀects of AS-IV
on Wnt/β-catenin signaling in primary keratinocytes under
LiCl-inducedconditions.Theseﬁndingsrevealapositiverole
forAS-IVincutaneouswoundhealingviadownregulationof
β-catenin expression.
2.MaterialsandMethods
2.1. Chemicals and Reagents. AS-IV (99.2% purity) was pur-
chased from the National Institute for the Control of Phar-
maceutical and Biological Products (Shanghai, People’s
Republic of China) and completely dissolved in room tem-
perature DMSO at a stock concentration of 20mg/mL. DAPI
was purchased from Roche Diagnostic Corp. (Indianapolis,
IN, USA). Bromodeoxyuridine (BrdU) detection kit was
purchased from BD Biosciences (San Diego, CA, USA).
LiC1 (pro analysis grade) was from Sigma-Aldrich (St.
Louis, MO, USA). Antibodies against β-catenin and GAPDH
were purchased from Cell Signaling Technology (Beverly,
MA, USA). Guinea pig anti-K14 was purchased from RDI-
Fitzgerald (Oaklyn, NJ, USA). Antibody against β-tubulin
was purchased from Sigma-Aldrich. Immunoﬂuorescence
secondary antibodies, Alexa Fluor 488-conjugated (green)
and Alexa Fluor 594-conjugated (red), were from Invitrogen
(Carlsbad, CA, USA). Fetal calf serum (FCS) and other cell
culture reagents, unless otherwise indicated, were from
Gibco (Invitrogen).
2.2. Cell Culture. Primary mouse keratinocytes were pre-
pared from newborn mice, as previously described [12],
and cultured at 37◦Ci na na t m o s p h e r eo f5 %C O 2 in Cnt-
07 medium with appropriate supplements (Cellntec, Berne,
Switzerland).
2.3. Cell Proliferation (MTS/PMS) and BrdU Incorporation
Assays. Cell proliferation was assayed using the MTS/PMSEvidence-Based Complementary and Alternative Medicine 3
method. Brieﬂy, cells (1 × 103/well) were plated in 96-well
culture plates (Nunclon; Nunc, Roskide, Denmark). After
overnight incubation, cells were treated in the absence or
presenceofLiClandAS-IV.Eachconcentrationwasregarded
as a single treatment group, while the control group only
contained DMSO. Each group contained six replicate wells.
After culture plates were incubated for 0, 24, 48, or 72h,
100μL of MTS/PMS working solution was added to each
well,andthekeratinocyteswerethenincubatedcontinuously
for another 4h. The absorbance (A value) of each well
wasmeasuredusingaspectrophotometer(BeckmanCoulter;
Miami, FL, USA) at 490nm. The eﬀect of AS-IV on the
cell growth inhibitory rate in keratinocytes was calculated
according to the following formula: % inhibitory rate = [A490
value of treated group]/[( A490 value of control group) ×
(100%)]. The 50% inhibitory concentration (IC50)w a s
determined from dose-response data from at least three
independent experiments. Cell number and cell viability
were determined daily using a Coulter Counter (Beckman
Coulter-Z2) and the trypan blue dye exclusion test. For the
5-bromo-2 -deoxyuridine (BrdU) incorporation assay, cells
were seeded and serum starved as above. After treatment
with PBS or LiCl at diﬀerent concentrations for 12h in 10%
FBS-containing media, cells were incubated with BrdU for
an additional 2h. BrdU-labeled cells were detected using an
enzyme-linked immunosorbent assay- (ELISA-) based col-
ormeric kit (BD Biosciences; San Diego, CA, USA) according
to the protocol provided by the manufacturer.
2.4. Western Blot Analysis. Lysates from cultured cells were
prepared as previously described [13]. Whole cell protein
extracts were resolved by SDS-PAGE and electrotransferred
to membranes for speciﬁc antibody detection as previously
described [14].
2.5. In Vitro Scratch Assay. When mouse keratinocytes
reached 100% conﬂuency, cells were transferred to basal
KBM medium (Life Technologies, Inc., Grand Island, NY,
USA) and incubated for 24h. Cells were then treated with
8μg/mL mitomycin (ICN, Irvine, CA, USA) for 1h and then
washed with basal media. LiCl, an inhibitor of glycogen
synthase kinase 3 (GSK3), was applied to activate Wnt sig-
naling. Since LiCl can also eﬃciently block EGF-stimulated
migration,EGF-inducedcellmigrationwasusedasapositive
c o n t r o l .S c r a t c h e sw e r ep e r f o r m e di nt r e a t e dc e l lc u l t u r e sa s
previouslydescribed,andcultureswerephotographed.Then,
mixtures of 20μmol/L LiCl with or without 25ng/mL EGF
and 80μg/mL AS-IV were added to the cultures and incu-
bated for 24h, 48h, or 72h. The cells were rephotographed,
and comparisons to the pre-treatment images were used
to quantitatively determine the extent of cell migration as
previously described. Brieﬂy, the distance covered by a cell
moving into the scratch wound area was measured. Thirty
measurements were taken for each experimental condition.
Three images were analyzed per condition and per time
point.
2.6. Flow Cytometry for Cell Cycle Analysis. Cells were plated
at a density of 1.5 × 106 cells per 6cm diameter dish and
allowed to grow for 24h, after which the medium was
changed to serum-free medium. After 16–18h of starvation,
cells are synchronized in the G0 phase of the cell cycle. Dif-
ferent experimental reagents were then added to the serum-
free medium and incubated for the indicated times. Cells
(1 × 106) were harvested by trypsinization, washed twice in
cold PBS, and ﬁxed in 70% alcohol for 30min on ice. After
washing in cold PBS three times, cells were resuspended in
1mLKrishanstainingsolution[15]andleftovernightat4◦C.
The next day, cells were ﬁltered through a 96-micron pore
size nylon mesh, and a total of 10000 stained nuclei were
analyzed with a ﬂow cytometer (BD Biosciences). DNA
histograms were prepared using the accompanying ModFit
analysis program (BD Biosciences), which plots and statis-
tically ﬁts the fractions of cells in the G0-G1,S ,a n dG 2-M
phases. Each condition was repeated in triplicate.
2.7. Immunoﬂuorescence Staining. Cells were cultured on
8-well chamber slides (Thermo Fisher Scientiﬁc, Waltham,
MA, USA) and treated with diﬀerent concentrations of AS-
IV for 24h. Cells were then ﬁxed with 4% paraformaldehyde,
permeabilized with 0.3% Triton X-100, and digested in
pepsinsolution(LabVision,ThermoFisherScientiﬁc).Non-
speciﬁc binding in crude protein extracts was blocked by
incubating cells in 10% normal goat serum plus 0.1% NP-
40 for 1h. Detection of speciﬁc proteins was carried out by
incubating with primary antibodies overnight. Alexa Fluor
488- or 594-conjugated secondary antibodies were used for
immunoﬂuorescence staining, and images were obtained
with a Leica SP2 confocal microscope (Deerﬁeld, IL, USA).
2.8.StatisticalAnalysis. Dataarepresentedasthemean ±SD
of at least three independent experiments, unless designated
otherwise. Statistical analysis was carried out using Student’s
t-Test, and a value of P<0.05 was considered to be signiﬁ-
cant.
3. Results
3.1. AS-IV Attenuates LiCl-Induced Inhibition of Keratinoctye
Growth. To investigate the normal function of the Wnt
signaling pathway in keratinocytes, we used LiCl to activate
the Wnt/β-catenin signaling pathway. The eﬀect of LiCl on
keratinocyte proliferation was examined by the MTS/ PMS
assay and measurement of BrdU incorporation into DNA
during DNA synthesis. As shown in Figure 2(a),k e r a t -
inocytes were treated with diﬀerent concentrations (0∼
40.0mM/L) of LiCl for 24, 48, and 72h. Controls were sub-
conﬂuent and synchronous keratinocytes were treated with
DMSO solvent alone for the indicated times. Compared to
the control group, LiCl-treated keratinocytes exhibited con-
sistent growth retardation. The half maximal (50%) inhi-
bitory concentration (IC50)v a l u e s( Figure 2(a), dotted line)
of growth achieved after LiCl-treatment for 24, 48, and 72h
were 25.85 ± 5.03, 16.16 ± 0.95, and 12.35 ± 1.38mM,
respectively. Lower concentrations of LiCl (<5mM) did not
inhibit keratinocyte growth. Higher concentrations of LiCl4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Cell proliferation of keratinocytes in response to LiCl and AS-IV treatment. (a) LiCl inhibits proliferation of mouse keratinocytes,
as evidenced by the MTS/PMS assay. Data are expressed as a percentage of the control (100%) and represent the mean ± SD of three
experiments. ∗P<0.05, ∗∗P<0.01. (b) LiCl induced a senescent-like morphology in live keratinocytes, as evidenced by phase-contrast
microscopy. (c) Growth curve of keratinocytes in response to LiCl and AS-IV treatments. (d) OD at 490nm of keratinocytes treated with or
without LiCl and AS-IV for 72h. Scale bar = 100μm.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: BrdU staining of cells treated with LiCl in the absence of presence of AS-IV. (a) LiCl treatment produced a concentration-
dependentdecreaseinBrdU-positivecellscomparedtocontrolcells.(b)Histogramsrepresentthemean ±SDofthepercentofBrdU-positive
cells treated with diﬀerent concentrations of LiCl. (c) Changes in β-catenin protein expression in response to LiCl. (d, e, f) Comparison of
the eﬀects of LiCl ± AS-IV on cell proliferation, by detection of BrdU incorporation and β-catenin protein expression. AS-IV resolved LiCl-
inducedinhibitionofcellproliferationanddownregulation of β-catenin. ∗P<0.05. ExpressionofK14 andGAPDH were detected as protein
loading controls Scale bar = 100μm.
(>5mM) produced signiﬁcant and dose-dependent inhibi-
tion of keratinocyte proliferation (Figure 2(a),c i r c l e ) .T h e
BrdU incorporation assay also revealed a concentration-
dependent decrease in BrdU-positive cells in response to dif-
ferent dosages of LiCl. As shown in Figure 3(a), the amount
of BrdU-positive cells following LiCl-treatment of 10mM
(57.91 ± 6.57%), 20mM (23.48 ± 3.19%), and 40mM
(9.67 ± 2.45%) was signiﬁcantly less than those in the
DMSO-treatment control group (71.81 ± 6.79%; all P<
0.01). Cell viability was unaﬀected by LiCl-treatment at all
doses (Figure 4(c)). These data unambiguously conﬁrm that
LiCl is able to exert potent growth inhibitory eﬀects on6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: LiCl aﬀects keratinocyte morphology but not cell viability. Treatment with 20mM and 40mM LiCl caused cell size to enlarge (a,
red arrow). (b) Average cell size from three experiments. (c) LiCl treatment had no eﬀect on keratinocyte viability, as evidenced by the cell
viability assay.
keratinocytes in a concentration- and time-dependent man-
ner. These results also indicate that LiCl-treatment inhibits
keratinocyte proliferation without aﬀecting their viability.
To investigate the function of AS-IV in keratinocytes
overexpressing β-catenin, we incubated the cells with AS-
IV and LiCl for 72h. As shown in Figures 2(c) and 2(d),
AS-IV treatment attenuated LiCl-induced inhibition of cell
proliferation, as evidenced by the fact that optical density
(OD) at 490nm was signiﬁcantly higher in the LiCl group
than in the DMSO control group (P<0.05). Similarly, the
BrdUassayshowedthatAS-IVtreatmentwasabletoenhance
the percentage of positive cells (from 23.48% to 31.05%;
Figure 3(e)), suggesting that AS-IV was able to promote
DNA synthesis.
3.2. LiCl Induces Senescence-Like Changes in Keratinocytes.
LiCl treatment also led to obvious morphological changes
in keratinocytes, including increased size, spreading, and
ﬂattened appearance. There were no rounded cells, char-
acteristic of apoptosis, observed in LiCl-treated cultures
(Figure 2(b)). Using the cell viability assay, we measured the
change in diameter of keratinocytes in response to exposure
to diﬀerent doses of LiCl (from 10mM to 40mM) for 48h.
As shown in Figure 4, LiCl treatment at doses of 20mM
a n d4 0 m Mr e s u l t e di na ne n l a r g e dc e l ls i z e( Figure 4(a),
red arrow), which indicated that high concentrations of LiCl
maychangekeratinocytemorphology.Theaveragediameters
of LiCl-treated keratinocytes were greater (10mM, 16.45 ±
1.36μm; 20mM, 16.59 ± 0.36μm; 40mM, 17.72 ± 1.01μm)
than that in the control group (15.23 ± 0.97μm).
3.3.AS-IVAttenuatesLiCl-InducedSPhaseCellCycleArrestin
Keratinocytes. LiCl-induced inhibition of growth may result
from cell cycle eﬀects. Thus, the cell cycle distribution of
LiCl-treated and control cells was determined by measuring
theDNAcontentofKrishan-stained cellsusingﬂuorescence-
activated cell sorting. As shown in Figure 5, LiCl-treated
cells exhibited a higher proportion of cells in the S phase
thancontrolcells.Histogramsweregeneratedtovisualizethe
percent of cell cycle distributions produced by diﬀerent LiCl
concentrations (Figure 5(b)) and diﬀerent exposure times
(Figure 5(c)). Interestingly, when LiCl-treated cells wereEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: LiCl induces S phase arrest in keratinocytes. (a) Keratinocytes were exposed to various concentrations of LiCl for 24h. (b)
Keratinocytes were exposed to 20mM LiCl for 24h, 48h, and 72h. (c) Histogram showing the average amounts of cells in various cell cycle
stages from three experiments following a 24h exposure to diﬀerent LiCl concentrations. (d) Histogram showing the average distribution of
cells in various cell cycle stages from three experiments with LiCl ± AS-IV, and LiCl + EGF treatments.
exposed to AS-IV, there was remarkable attenuation of
induced cell cycle arrest in the S phase. Speciﬁcally, the per-
centage of S phase cells in LiCl-treated keratinocytes cultures
wentfrom48.81 ±7.43to35.28 ±2.14uponAS-IVexposure
(P<0.05).
3.4. AS-IV Attenuates LiCl-Induced Overexpression of β-Cat-
enin in Keratinocytes. We investigated the eﬀect of AS-IV on
β-Catenin expression in primary keratinocytes using two
standard assays, namely immunoﬂuorescence staining and
Western blot analysis. As expected, keratinocytes incubated8 Evidence-Based Complementary and Alternative Medicine
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with EGF showed normal β-catenin membrane expression,
but those treated with LiCl exhibited prominent nuclear
β-catenin staining. LiCl-induced nuclear β-catenin was at-
tenuated by AS-IV exposure, as evidenced by remarkably
less β-catenin nuclear staining (Figure 6(a)). Similarly, West-
ern blot analysis indicated that LiCl-treated keratinocytes
expressed over 5-fold more β-catenin than the control cells.
In addition, AS-IV exposure of LiCl-treated cells led to
nearly 3-fold less β-catenin that that in the control group
(Figure 6(b)) and additionally, PCNA, which indicating the
cell proliferation, was downregulated 50% by LiCl compared
with DMSO control, and upregulated to 80% by AS-IV
(Figure 6(c)).
3.5. AS-IV Attenuates LiCl-Induced Migration Inhibition of
Keratinocytes. To test if LiCl-induced overexpression of β-
catenin can aﬀect keratinocyte migration during wound
healing, we used the in vitro wound scratch assay. Ker-
atinocytes were incubated with LiCl, LiCl and EGF (positive
control), and/or AS-IV for 72h. Keratinocyte migration into
the scratch area was observed and the distance was quan-
tiﬁed. As shown in Figure 7, LiCl treatment inhibited ker-
atinocyte migration by almost 80%, whereas LiCl and AS-IV
promoted migration by 60%, presumably via downregula-
tion of activated β-catenin.
3.6. AS-IV Attenuates LiCl-Induced Downregulation of β-
Tubulin. Tubulin protein is a key mediator of cell migration
[16]. To determine whether LiCl treatment aﬀected β-
tubulin expression, we incubated primary keratinocytes with
LiCl alone or with AS-IV. Changes in β-tubulin expression
levels were evaluated by immunoﬂuoresence following stain-
ing of treated cells with a β-tubulin-speciﬁc antibody (Figure
8(a)), and by immunoblotting (Figure 8(c)). β-tubulin wasEvidence-Based Complementary and Alternative Medicine 9
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Figure 7: AS-IV attenuates LiCl-induced inhibition of keratinocyte migration. (a) Mouse primary keratinocytes with LiCl-induced
activation of β-catenin were used in the scratch assay. LiCl inhibited keratinocyte migration compared to untreated cells. Inhibition was
prominent at 48h and was sustained through 72h (∗∗P<0.01). EGF (positive control) stimulated migration was signiﬁcant after 72h,
as evidenced by the nearly closed wound. AS-IV attenuated the LiCl-induced keratinocyte migration inhibition eﬀect, as evidenced by the
diﬀerence in wound closure after 72h (∗P<0.05, compared with LiCl-treated group). Straight lines demarcate the initial wound area, and
dotted lines indicate the migrating front of cells. (b) β-catenin was upregulated at the scratch wound edge. Insets show enlarged images of
the dotted rectangle. The white circle indicates the keratinocytes starting to migrate from the nonnuclear β-catenin-positive cell. Scale bar =
100μm.(c)Histogramsshowingtheaveragecoverageofscratchwoundswidthsaspercentagesofthebaselinewoundwidthattimeofscratch
(0) and 24h, 48h, and 72h after LiCl, LiCl + AS-IV, and LiCl + EGF treatments. ∗P<0.05, ∗∗P<0.01. Scale bar = 100μm.
expressed in most of the untreated primary keratinocytes,
but LiCl-treatment reduced β-tubulin expression. As shown
in Figure 8(b), β-tubulin was expressed in only 15% of LiCl-
treated cells but was expressed in 27% of cells treated with
LiCl and AS-IV. In the DMSO-treated control cultures, 80%
of cells expressed β-tubulin. Together, our ﬁndings indicate
that LiCl is able to cause downregulation of β-tubulin, which
was resolved, at least in part, by treatment with AS-IV. Thus,
overexpression of β-catenin during the wound healing pro-
cess may impair healing by reducing β-tubulin expression,
and subsequently inhibiting keratinocyte migration. Since
AS-IV can attenuate LiCl-induced downregulation of β-
tubulin, it may represent a promising therapeutic agent for
improving migration and promoting wound healing.
4. Discussion
In developed countries, 0.2 to 1% of the population is af-
fected by chronic venous ulcers [17]. In China, it has
been reported that approximately 1.5%–3.0% of surgical10 Evidence-Based Complementary and Alternative Medicine
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Figure 8: AS-IV attenuates LiCl-induced β-tubulin downregulation. Keratinocytes were treated with LiCl (20mM) and LiCl (20mM) +
AS-IV (80μg/mL) for 24h, and β-tubulin was determined by immunoﬂuorescence (a, merged images of K14/β-tubulin/DAPI were shown)
and immunoblotting ((c), GAPDH protein expression was used as the protein loading control). (b) Cell numbers of β-tubulin-positive
keratinocytesper100totalcellsarepresented.AS-IVsigniﬁcantlyattenuatedLiCl-inducedβ-tubulindownregulation. ∗P<0.05, ∗∗P<0.01.
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inpatients are hospitalized for chronic refractory wounds.
Nonhealing chronic wounds not only decrease the quality of
life of the suﬀerer and increase risk of further infection and
death, but also represent a signiﬁcant economic burden on
the healthcare system. The experiments described in the
present study show that AS-IV is able to repair chronic cut-
anous wounds through regulation of cell migration and cell
proliferation.
Among the many biological molecules known to inﬂu-
ence wound healing, Wnt signaling is believed to be crucial,
as it mediates skin development throughout life and can
exert both positive and negative eﬀects on the wound healing
process. LiCl is a well-characterized inhibitor of GSK3, and
as such can eﬀectively activate Wnt signaling in vitro [10].
NumerousstudieshaveshownthatLiClcanelicitremarkably
various eﬀects on diﬀerent cell types. For instance, LiCl was
shown to stimulate proliferation of cultured erythrocytes
via activation of the Wnt/β-catenin signaling pathway [18].
In addition, LiCl-stimulated proliferation of MCF-7 human
breast cancer cells and caused a remarkable change in the
expression of phosphoinositide metabolites [19]. In con-
trast, administration of LiCl suppressed prostate cancer cell
proliferation by disrupting the E2F-DNA interaction and
subsequent E2F-mediated gene expression [20]. LiCl also
inhibited proliferation of the human esophageal cancer cell
line, Eca-109, by inducing G2/M cell cycle arrest [21]. Mao
et al. reported that LiCl treatment induced cell cycle arrest
in G2/M in primary bovine aortic endothelial cells without
aﬀecting cell viability [22]. These studies demonstrate that
LiCl can mediate a wide variety of cellular functions depend-
ing on the context. Here, we demonstrate that LiCl can
induce cell proliferation and migration inhibition and cause
S phase arrest in mouse primary keratinocytes (Figure 5).
The important role of Wnt signaling pathway activation
in wound healing is well recognized [23, 24]. The Wnt
signaling pathway is known to regulate a variety of cell func-
tions, including cell fate, polarity, and diﬀerentiation, via the
canonical or β-catenin stabilization pathway and/or the pla-
nar cell polarity or noncanonical pathway [25]. In addition,
Wntsignaling waspreviouslyshowntomediateproliferation
and migration of ﬁbroblasts and keratinocytes [26]. Ker-
atinocytes, the major cellular component of the epidermis,
have several critical roles in the wound healing process. The
keratinocytes that appear at the nonhealing edges of chronic
wounds have been shown to overexpress β-catenin protein
andarebelievedtodiﬀerfromnormal,healthykeratinocytes.
During the normal wound healing process, the re-
epithelialization stage involves covering the wound surface
with a layer of epithelium, which involves diﬀerentiation,
proliferation, and migration of epidermal keratinocytes.Evidence-Based Complementary and Alternative Medicine 11
Research has shown that overexpression of β-catenin and
c-myc contributes to impaired wound healing by inhibiting
keratinocyte migration and altering their diﬀerentiation.
A previous study from our laboratory also indicated that
a Chinese formula that included Radix astragali ingredients
might be eﬀective in regulating the Wnt signaling pathway
[11]. However, the underlying mechanisms have remained
ambiguous. AS-IV is the major phytochemical compound
of the well-known Chinese herbal medicine Huangqi, which
is extracted from the dried root of Radix astragali, and is
a widely used herbal remedy in traditional Chinese medi-
cine for the treatment of diabetes and inﬂammation [7].
Therefore, the goal of the present study was to determine the
eﬀect of AS-IV on keratinocyte proliferation and migration
in wound healing.
In this report, we show that treatment of primary ker-
atinocytes with LiCl, an inhibitor of GSK-3β and an acti-
vator of the Wnt signaling pathway, induced stabilization
and nuclear translocation of β-catenin associated with cell
proliferation and migration inhibition. Moreover, LiCl treat-
ment signiﬁcantly induced cell cycle arrest in the S phase.
MTS/PMS and cell viability assays showed that LiCl induced
cell growth retardation without aﬀecting cell viability; it
appeared that this eﬀect was a result of induction of a
senescent-like phenotype. AS-IV treatment of LiCl-induced
keratinocytes resulted in attenuated growth retardation and
reduced amounts of cells in the S phase. These new ﬁndings
led us to hypothesize that β-catenin overexpression during
impaired wound healing may account for the dysfunctional
keratinocyte proliferation and migration.
In our study, the BrdU incorporation assay was used
to determine DNA synthesis activity as an indirect method
of evaluating cell proliferation. BrdU analysis showed that
AS-IV treatment was able to increase the percentage of
BrdU-positive cells (Figure 3(e)), indicating that AS-IV can
eﬀectively promote DNA synthesis activity in keratinocytes.
Keratinocyte migration is essential for skin wound healing.
Treatment with LiCl alone inhibited keratinocyte migration
abilities in a wound scratch assay. Interestingly, β-catenin
was upregulated at the scratch wound edge in LiCl-induced
keratinocytescultures.AS-IVeﬀectivelyattenuatedthisLiCl-
induced migration inhibition eﬀect (Figure 7). Moreover, we
found that keratinocytes started to migrate from the non-
nuclear β-catenin positive cell, indicating that the migration
of β-catenin-positive cells is blocked and AS-IV treatment
improves cell migration associated with β-catenin expres-
sion.
In summary, using LiCl as a tool to activate Wnt/β-
catenin signaling, we have shown the functional relevance
of Wnt/β-catenin signaling in keratinocyte proliferation and
migration. Importantly, we have also provided evidence for
the application of AS-IV in the treatment of wound healing
and revealed its role in the wound healing reepithelialization
stage. These AS-IV related discoveries provide novel insights
into the molecular mechanisms underlying the signiﬁcant
regulation of the proliferative eﬀects of AS-IV in keratino-
cytes, which can enhance epithelialization and healing of
chronic wounds [27]. Future studies are needed to further
elucidate the eﬀect of AS-IV on other molecules and cells
involved in wound healing, as this will help to advance the
development of this drug for clinical application.
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